Refine your search

Content type
Tags
Author
Jurisdiction
Language

310 results found

Commentary
Ask Lexy

Smart & Biggar | Canada | 27 Oct 2021

Regulatory amendments provide permanent measures to address therapeutic product shortages

The Regulations Amending Certain Regulations Concerning Drugs and Medical Devices (Shortages) were recently published in Part II of the Canada Gazette. These amendments are intended to provide Health Canada with permanent regulatory tools to help prevent or alleviate therapeutic product shortages.
Article
Ask Lexy

CPST Intellectual Property | Canada | 16 Jun 2020

Data Protection for Innovative Drugs in Canada

Canada, like many other countries, has a system of data protection for innovative drugs. The purpose of this article is to provide an overview of the…
Article
Ask Lexy

Stikeman Elliott LLP | Canada, Mexico, USA | 18 Feb 2020

Update on the Canada-United States-Mexico Agreement (CUSMA)

On December 10, 2019, the Governments of Canada, the United States and Mexico executed the Protocol of Amendment to the Agreement between Canada, the…
Article
Ask Lexy

Bristows | European Union, United Kingdom | 13 Feb 2020

CBD - Could be done for?

Today the Food Standards Agency (FSA) announced that Products Containing cannabidiol (CBD) Extracts must be the subject of a valid application with…
Article
Ask Lexy

McDermott Will & Emery | USA | 7 Jun 2019

Learnings from the FDA Hearing on Cannabis and Cannabis-Derived Compounds

On Friday May 31, 2019, the Food and Drug Administration (FDA) held a public hearing on the topic of cannabis or cannabis-derived compounds. The FDA…
Article
Ask Lexy

Michael Best & Friedrich LLP | USA | 22 May 2019

Supreme Court Empowers Judges to Resolve Preemption Defenses in Failure-to-Warn Drug Labeling Cases

On Monday, May 20, the Supreme Court of the United States issued a significant decision that should inform products liability defense strategies. In…
Commentary
Ask Lexy

Smart & Biggar | Canada | 27 Mar 2019

Health Canada publishes guidance document on post-market drug benefit-risk assessments

Health Canada recently published its "Overview of the format and content for post-market drug benefit-risk assessment in Canada – guidance document". The objective of the guidance document is to assist market authorisation holders in developing a post-market benefit-risk assessment for a marketed drug when requested.
Article
Ask Lexy

Osler Hoskin & Harcourt LLP | Canada | 20 Mar 2019

Legislative Update Report No. 2019-06 Le Bulletin d'actualités législatives

An Act respecting certain payments to be made out of the Consolidated Revenue Fund…
Article
Ask Lexy

Blake, Cassels & Graydon LLP | Canada | 20 Feb 2019

Up in the Air: Health Canada Considers Further Restrictions for Vaping Product Advertising

Health Canada recently proposed measures to reduce the impact of vaping product advertising on youth and non-users of tobacco products. If…
Article
Ask Lexy

Bereskin & Parr LLP | Canada | 11 Feb 2019

Small Claims Court grants Trademark Relief — Seems Kosher

The recent small claims court decision in Kashruth Council of Canada v 1412189 Ontario Inc., 2018 CanLII 130064 saw the Ontario Small Claims Court…
Previous page 1 2 3 ...